Promising results reported for novel antiangiogenic agents for neuroendocrine tumours
The fields of metastatic pancreatic NETs and advanced and low proliferative grade 3 disease tumours move forward
Novel immunotherapeutics suggest promise in high-grade gliomas
Results from early-phase studies reveal potential for a new cancer vaccine and adaptive immunotherapy
Further support for durvalumab consolidation as a new standard of care in limited-stage SCLC
Subgroup analyses from the ADRIATIC study support previous practice-changing findings
Multi-gene ctDNA profiling effectively matches patients with advanced cancer to targeted therapies
In France, a nationwide programme aims to broaden access to the technology based on the positive results collected so far
From precision oncology to molecular prevention – a new role for our profession?
As rapid scientific and technological progress raises hopes of more cancers being intercepted at the earliest stages in the future, ESMO delves deeper into prevention to ensure education and guidance for medical oncologists in this moving field
Cancer in old patients: geriatric assessment and management plays a crucial role to provide personalised care
First recommendations are released from the ESMO/SIOG Cancer in the Elderly Working Group
First gene engineered T-cell therapy for solid tumours confirmed to be a promising tool
The positive results of the SPEARHEAD-1 trial which showed durable responses of afamitresgene autoleucel in unresectable or metastatic synovial sarcoma granted FDA accelerated approval
First-line avimantamab plus lazertinib shows efficacy in patients with high-risk EGFR-mutant advanced NSCLC
In the MARIPOSA study, a significant improvement in progression-free survival was reported in a subgroup with poor prognostic factors
Eftilagimod alpha plus pembrolizumab shows promise in HNSCC with negative PD-1 expression
In the Cohort B of the TACTI-003 study, the combination therapy led to clinically meaningful response rates in patients with recurrent or metastatic disease
How to interpret genomic testing results? ESMO recommendations to make reports easy to read
The aim is to harmonise results between different laboratories and facilitate clinical decision-making for physicians